IN what amounted to a rare display of shareholder muscle, the Elan board failed yesterday in its attempt to secure passage of a resolution, which would have increased its fundraising options.

ELAN CORPORATION is seeing significant "unsolicited interest" from several quarters in its assets, according to company chairman Garo Armen.

Kyran Fitzgerald reports on Elan’s dramatic and devastating fall from grace.

The US-owned Elan Pharmaceutical company is to cut its 900-strong Irish workforce by more than a third.

ELAN shares have been given an "avoid" rating by Merrion Stockbrokers in the wake of the company's global conference call to investors yesterday when plans to raise €1 billion in an asset sell-off were unveiled.